Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer, which is relatively resistant to anti-programmed cell death-1 (α-PD1) therapy, characterized as non-immunogenic, dense stroma and accumulation of M2 tumor-associated macrophages (TAMs). Despite progress in st...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Qing, He, Xuexin, Qin, Xiyi, Liu, Yu, Jiang, Han, Wang, Jing, Wu, Shuang, Zhou, Rui, Yu, Congcong, Liu, Suling, Zhang, Hong, Tian, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259940/
https://www.ncbi.nlm.nih.gov/pubmed/35812418
http://dx.doi.org/10.3389/fimmu.2022.938439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259940/
https://www.ncbi.nlm.nih.gov/pubmed/35812418
http://dx.doi.org/10.3389/fimmu.2022.938439

Ejemplares similares